C-EQAXDorian Therapeutics
cell rejuvenation, cellular resilience
reprogrammingepigenetic reprogramming
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EQAX
C-EQAXC-EQAXcell rejuvenation, cellular resilience
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Altos Labs Inc. H1B Visa Data - Salaries, Applications & Approval Rates | H1BTrends H1BTrends H1B PERM Reports Green Card Calculator NEW H1B Lottery Odds Calculator (FY 2027) Immigration Updates Loading company data... Analyzing thousands of H1B applications Fetching applications Calculating statistics Preparing insights H1BTrends Search 3M+ H1B LCA and PERM labor certification applications from the U.S. Dept. of Labor. Find H1B sponsoring companies, compare salaries by job title and city, check approval rates, and explore employment-based green card data. Data reflects the most recent fiv … ross different markets. The data above is sourced from official Labor Condition Application (LCA) records filed with the U.S. Department of Labor. H1B visa sponsorship data is updated quarterly to reflect the most recent filings and approval decisions. Data sourced from U.S. Department of Labor disclosure files. Last updated: 2026-05-17T08:48:04.911Z Frequently Asked Questions about Altos Labs Inc. H1B Sponsorship Does Altos Labs Inc. sponsor H1B visas? What is the average H1
What are the Porter's Five Forces of Altos Labs – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 Home Healthcare Altos labs porter's five forces template research ALTOS LABS PORTER'S FIVE FORCES TEMPLATE RESEARCH Digital Product Download immediately after checkout Editable Template Excel / Google Sheets & Word / Google Docs format For Education Informational use only Independent Research Not affiliated with referenced companies Refunds & Returns Digital product - refunds handled per policy ALTOS LABS BUNDLE Get the Full Package: 5 Forc … ated disease costs. High-Net-Worth Early Adopters High-net-worth early adopters fund longevity-as-a-service, often covering initial per-patient fees of $250k-$1M in 2025, so they provide critical bridge revenue while trials continue. Their willingness to pay is high, but demand for proven efficacy and safety gives them outsized influence on Altos Labs' reputation and product roadmap. In 2025 their feedback drove changes to delivery mechanisms in ~30% of pilot cases, accelerat
Altos Labs - Privacy Policy About About Science Careers Careers Featured Contact Privacy Policy PRIVACY NOTICE PRIVACY NOTICE Last updated May 1, 2025 Last updated May 1, 2025 Thank you for choosing to be part of our community at Altos Labs, Inc. (" Company ," " we ," " us ," or " our "). As the controller of the personal information we process via this website, we are committed to protecting your personal information and your right to privacy. If you have any questions or concerns about this privacy notice or our practices regarding your personal inform … a may include information such as your IP address (or proxy server), device and application identification numbers, location, browser type, hardware model, Internet service provider and/or mobile carrier, operating system and system configuration information. Device Data. We collect device data such as information about your computer, phone, tablet or other device you use to access the Website. Depending on the device used, this device data may include information such as you … a may include information such as your IP address (or proxy server), device and application identification numbers, location, browser type, hardware model, Internet service provider and/or mobile carrier, operating system and system configuration information. Location Data. We collect imprecise location data such as information about your device's location. How much information we collect depends on the type and settings of the device you use to access the Website. Locat
What are the Porter's Five Forces of Altos Labs – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 Home Healthcare Altos labs porter's five forces template research ALTOS LABS PORTER'S FIVE FORCES TEMPLATE RESEARCH Digital Product Download immediately after checkout Editable Template Excel / Google Sheets & Word / Google Docs format For Education Informational use only Independent Research Not affiliated with referenced companies Refunds & Returns Digital product - refunds handled per policy ALTOS LABS BUNDLE Get the Full Package: 5 Forc … ated disease costs. High-Net-Worth Early Adopters High-net-worth early adopters fund longevity-as-a-service, often covering initial per-patient fees of $250k-$1M in 2025, so they provide critical bridge revenue while trials continue. Their willingness to pay is high, but demand for proven efficacy and safety gives them outsized influence on Altos Labs' reputation and product roadmap. In 2025 their feedback drove changes to delivery mechanisms in ~30% of pilot cases, accelerat
Dorian Therapeutics Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribut … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Dorian Therapeutics - overview Established 2018 Location San Carlos, CA, US Primary Industry Biotechnology About Dorian Therapeutics is a biotechnology company based in the U. S. focused on developing innovative therapies aimed at combating cellular aging and enhancing healthspan through advanced cellular … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
Invest In Altos Labs Stock | Buy Pre-IPO Shares | EquityZen We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences Sign Up Today and Learn More About Altos Labs Stock Invest in or calculate the value of your shares in Altos Labs or other pre-IPO companies through EquityZen's platform. Get Started View More Companies Altos Labs Stock Altos Labs focuses on cellular rejuvenation programming to restore cell health and resilience, to reverse disease to transform medicine. Invest Now Sell Shares About Altos Labs Stock Founded 2021 Headquarte … their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investmen … on FINRA’s BrokerCheck . EquityZen Inc. was awarded a 2024 Fintech Breakthrough Award by Tech Breakthrough LLC on March 19, 2025, based on the prior year and covering calendar year 2024, and has compensated FinTech Breakthrough LLC for use of its name and logo in connection with the award. FinTech Breakthrough LLC is a third party and has no affiliation with EquityZen. EquityZen created the ticker symbols referenced on this page for use solely on the EquityZen platform. They
What is Growth Strategy and Future Prospects of Altos Labs Company? – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 What Are the Growth Strategies and Future Prospects of Altos Labs? March 20, 2026 ALTOS LABS BUNDLE Get the Full Package: 5 Forces $15 $10 BCG Matrix $15 $10 Canvas $15 $10 Marketing Mix $15 $10 PESTLE $15 $10 SWOT Analysis $15 $10 TOTAL: ADD TO CART Can Altos Labs turn a $3 billion bet into a longevity revolution? Altos Labs burst into view in 2022 with an unprecedented $3 billion war chest and a mission to reset cellular a
Altos Labs About About Science Careers Careers Featured Contact About / Executive Leadership Hal Barron, MD CEO, Founder and Board Co-Chair CEO, Founder and Board Co-Chair " It’s clear from work by Shinya Yamanaka, and many others since his initial discoveries that cells have the ability to rejuvenate, resetting their epigenetic clocks and erasing damage from a myriad of stressors. These insights, combined with major advances in a number of transformative technologies, inspired us to establish Altos with a transformative mission, to reverse disease for patients. I care deeply about making
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Dorian Therapeutics Acquired by Altos Labs | M&A News | Signalbase Signalbase Signals Pricing API docs Login Get API access Login Get API access Toggle menu M&A news · Published May 21, 2025 Altos Labs Acquires Dorian Therapeutics: Advancing Neuropharmaceutical Innovations Dorian Therapeutics acquired by Altos Labs Acquisition Pharmaceuticals Get the full Dorian Therapeutics company profile Access contacts, investors, buying signals & more Open in Dashboard Acquired Dorian Therapeutics Pharmaceutical Manufacturing Undisclosed amount May 21, 2025 Acquirer Altos Labs Biotechnology Re
Member Spotlight: ALTOS Labs - Biocom Skip to main content Search Cancel Select Location Choose a location San Diego Greater Los Angeles Bay Area Seattle Sacramento Washington, D.C. Tokyo Enter your location ZIP Code Submit Location Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podcast Episodes About About Us Our Team Board of Directors Careers Contact Our Locations San … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Membership Member Benefits Become a Member Conference & Events Funding & Partnering Group Purchasing Policy & Advocacy Workforce Development International Connections Increase Visibility Community Building Catalyst: Innovators Under 40 CEO/Founder Network Converge … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podc
I am excited to share a new chapter for me and Dorian Therapeutics, which, as of this week, is now part of Altos Labs! Our program in cellular rejuvenation, which started years ago at Stanford… | Maddalena Adorno | 124 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update you
Altos Labs About About Science Careers Careers Featured Contact About / Board of Directors Dr. Rajiv Shah, MD Lead Independent Director Lead Independent Director " Altos Labs is taking on a scientific frontier that has the potential to transform human resilience to disease and illness and is doing so by creating a new platform for global scientific collaboration. I am excited about both the approach and the potential to lift up humanity. " Dr. Raj Shah is President of the Rockefeller Foundation, a global institution committed to promoting the well-being of humanity worldwide through
What is Growth Strategy and Future Prospects of Altos Labs Company? – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 What Are the Growth Strategies and Future Prospects of Altos Labs? March 20, 2026 ALTOS LABS BUNDLE Get the Full Package: 5 Forces $15 $10 BCG Matrix $15 $10 Canvas $15 $10 Marketing Mix $15 $10 PESTLE $15 $10 SWOT Analysis $15 $10 TOTAL: ADD TO CART Can Altos Labs turn a $3 billion bet into a longevity revolution? Altos Labs burst into view in 2022 with an unprecedented $3 billion war chest and a mission to reset cellular a
Altos Labs About About Science Careers Careers Featured Contact About / Board of Directors Robert Nelsen Director Director " Altos is driven by the kind of science whose potential impact keeps you up at night thinking. Combined with a biotech “dream team” to find medicines in the science. ARCH is privileged to back Rick, Hal, and Hans with our largest commitment ever. " Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150
Speaker: Cell Symposium: Advances in Therapeutic Applications of Stem Cells Cell Symposia Home Cell.com Home Program Conference Program Register Organizing Committee Speakers Submit Abstract Meet the Speakers dinner Supporting Publications Speaker Articles Marketing Resources Organizing Committee Related Meetings Walking Tour Social program --> Location Venue Accommodation Exhibition & Sponsorship Deadlines Help & FAQs Contact Us SIGN UP FOR UPDATES Speaker Juan Carlos Izpisua Belmonte, Altos Labs, USA Dr. Juan Carlos Izpisua Belmonte , previously the Roger Guillemin Chair and Professor in the … universal health therapeutics to overcome human. « Go Back Register Here Submit Abstract In collaboration with Supporting Publications Premium sponsor Silver Sponsor Exhibitors Financial Support Available Supported by Family Support Awards Premium Sponsor Sponsors --> Premier Sponsor --> In partnership with Exhibitors Sponsor --> Copyright © Elsevier Ltd , its licensors, and contributors. All rights are reserved, including those for t
Cell Rejuvenation Milestone Tracker (2026) – New Market Pitch Skip to content Home Startup News Blog About Us Contact Us Home Startup News Blog About Us Contact Us Search Cart Item added to your cart View cart Check out Continue shopping Cell Rejuvenation Milestone Tracker (2026) Last updated: 22 April 2026 In our longevity market deck , you will find everything you need to understand the market Cell Rejuvenation Milestone Tracker This table tracks 35 development milestones for four leading cellular reprogramming companies, with each cell rated Yes, No, Kind of, or Unclear based on publi
The Patent Office Comes to California - California Lawyers Association Skip to main content Trigger menu Close CLA ABOUT About CLA Leadership CLA News Advocacy Awards Bar Relations Diversity, Equity and Inclusion Sponsorship and Advertising Swag Store California Lawyers Foundation COMMITTEES Appellate Practice Network Cannabis Law Ethics Health and Wellness Environmental, Social and Governance Diversity Inclusion and Outreach All CLA Committees Membership MEMBERSHIP Member Benefits Membership Plans Discounts Free Legal Research Free Trust & Billing Software RESOURCES Career Center Law Student … E for CLA Members Awards Career Center Member Discounts Member Benefit Provider RFP 400 Capitol Mall, Suite 650 Sacramento, CA 95814 916-516-1760 [email protected] Link to Linked in Link to Facebook Link to Twitter Link to Instagram Link to YouTube Link to Flickr © 2026 CLA --> Terms Privacy Close this popup Login Email Password Remember me Sign In Forgot password? Not a member? Sign up Sign In Forgot Password Enter the email associated with you account. You will then r
What are the Porter's Five Forces of Altos Labs – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 Home Healthcare Altos labs porter's five forces template research ALTOS LABS PORTER'S FIVE FORCES TEMPLATE RESEARCH Digital Product Download immediately after checkout Editable Template Excel / Google Sheets & Word / Google Docs format For Education Informational use only Independent Research Not affiliated with referenced companies Refunds & Returns Digital product - refunds handled per policy ALTOS LABS BUNDLE Get the Full Package: 5 Forc … ated disease costs. High-Net-Worth Early Adopters High-net-worth early adopters fund longevity-as-a-service, often covering initial per-patient fees of $250k-$1M in 2025, so they provide critical bridge revenue while trials continue. Their willingness to pay is high, but demand for proven efficacy and safety gives them outsized influence on Altos Labs' reputation and product roadmap. In 2025 their feedback drove changes to delivery mechanisms in ~30% of pilot cases, accelerat
Concurrent Sessions — ISSCR 2026 0 Skip to Content program full agenda plenary sessions concurrent sessions program by scientific topic science spotlight sessions special sessions abstracts abstract submission travel, merit, & poster awards abstract reviewers networking meet-up hub receptions, lounges, & breaks one-on-one partnering sponsors & exhibitors sponsor, exhibit, & advertise current sponsors & exhibitors resources venue, hotel, & travel know before you go get involved official meeting journal promotional toolkit media resources child & family resource
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Longevity Technology Transfer: From Laboratory to Marketplace --> Toggle navigation About About Aims & Scope Why with Us Indexing Academic Editors Contact FAQ's Browse Covid-19 Research Early Online Current Issue Previous Issue Browse by Subjects Archive Practices Instructions Reviewer Guidelines Editor Instructions Submission Instructions Peer Review Timeline Peer Review Process Policies Open Access Membership Plans Plagiarism Policy Copyright Policy Terms and Conditions Other Scholar Awards Scholarship Grants Sponsors Benefits --> --> Bookmark Page views 3442 PDF Downlo … heir discussion focused primarily on regenerative medicine, the same principles apply to aging interventions. [21], documents how this regulatory gap forces longevity companies to adopt one of three suboptimal strategies: (1) narrowing their focus to a recognized disease indication, potentially underutilizing the technology's broader applications; (2) pursuing approval for an off-label use case, limiting reimbursement potential; or (3) marketing their intervention as a supple … trasting case study of technology transfer from academic research to commercial application. Founded in 2017 based on research from George Church's lab at Harvard Medical School, Rejuvenate Bio focused on gene therapy approaches to mitigate multiple aspects of aging simultaneously [21]. The company's technology transfer journey had several distinctive elements: Veterinary-first approach: Rather than immediately pursuing human applications, Rejuvenate Bio first targeted compan … distinctive characteristics that initially attracted investor interest: Focused application approach: Rather than targeting aging broadly, Unity selected specific indications, beginning with osteoarthritis, to create a clearer regulatory pathway. Strong IP position: The company secured exclusive licenses to foundational patents covering senolytic approaches, creating a defensible market position. Scientific credibility: The involvement of leading researchers in the aging fiel … oward alternative indications when initial approaches fail. This flexibility in application targeting represents an important risk mitigation strategy for longevity companies navigating uncertain development pathways. Unity's challenges illustrate the risks identified in Section 2.2 (extended validation timelines) and highlight why the alternativ
Exhibitor Manual | Longevity Summit Dublin 2026 Exhibitor Manual | Longevity Summit Dublin 2026 Exhibitor Manual on Longevity Summit Dublin 2026. The official website for the Longevity Summit Dublin 2026, a premier science-led. Pages Admin Ticket Applications — Admin Ticket Applications on Longevity Summit Dublin 2026. The official website for the Longevity Summit Dublin 2026, a premier science-led. Events — Events on Longevity Summit Dublin 2026. The official website for the Longevity Summit Dublin 2026, a premier science-led. Admin Settings — Admin Settings on Longevity Summit Dublin 2026. T
Isomorphic Raises $2.1 Billion Without Revealing a Single Drug Cand... | Plocamium About Our People James Tannahill Services News Global Insights Intelligence Network Entity Directory Insights Methodology Subscribe Contact Home Global Insights Isomorphic Raises $2.1 Billion ... Isomorphic Raises $2.1 Billion Without Revealing a Single Drug Candidate By James Tannahill · May 14, 2026 · 11 min read · Audio available Listen to this article 0:00 / --:-- 1x ✦ Takeaways by PlocamiumAI Hide ▲ Isomorphic Labs closed a $2.1 billion Series B financing without disclosing … th participation from Alphabet, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, notably excluding traditional biotech venture firms. Isomorphic has secured pharma partnerships including a $45 million upfront payment from Eli Lilly with up to $1.7 billion in potential milestones, plus undisclosed deals with Novartis and Johnson & Johnson, providing external validation despite no disclosed preclinical data. The company has raised $2.7 billion total since its 2023 spin … ereign wealth funds MGX and Temasek, alongside CapitalG and the UK Sovereign AI Fund . No traditional biotech venture firms participated. Isomorphic raised $600 million in Series A just over a year ago, bringing total capital raised to $2.7 billion since its 2023 spinout from DeepMind . The company said it would use the funds to scale its AI-driven drug design platform and advance internal programs toward human testing, without providing timelines or trial details . Demis Has … estors may lack, but it also imposes higher evidence barriers. Tech capital can fund larger, riskier preclinical outlier bets like Isomorphic and Altos, freeing life science VCs to focus on companies with more advanced pipelines . The implication: a bifurcation is emerging in biotech venture, with platform technology companies raising mega-rounds from generalist tech funds while asset-specific biotechs compete for traditional VC dollars. The risk rests with the tech investors … ch pharma partnerships may constrain. The Lilly, Novartis, and J&J deals likely grant those partners exclusive rights to resulting molecules, leaving Isomorphic with milestone and royalty economics rather than product ownership. If all value accrues to pharma partners, the venture returns compress, and the financing becomes a subsidized R&D engin
Steve Horvath - Integrative and Personalised Medicine 2026 Skip To Main Content REGISTER (opens in a new tab) Register Now (opens in a new tab) Conferences Show submenu for: Conferences Overview Conference Speakers Whole-Person Health Integrative Mental Health Integrative Oncology Food on Prescription Advanced Practitioner Conference Speakers Books Download Conference Programmes PDF Exhibition Show submenu for: Exhibition Exhibitor List Floorplan Sponsorship Opportunities Exhibit at IPM 2025 Attendance Workshops Show submenu for: Workshops Workshop Programme Wall-to-Wall Health Coaching Practi
Aging Research – Definition, Examples & Video Summaries | Summify Product Discover Pods Pricing Blog Login Get Started Capture Turn any content into structured knowledge Summarize YouTube TL;DR + key takeaways in seconds Transcribe YouTube Full searchable transcript with timestamps Translate YouTube Any video in 130+ languages PDF Summarizer Research papers, contracts, board packs Voice Notes Record, transcribe, structure ideas Interact Get more from what you've captured AI Chat Chat with any source — grounded with citations Deep Dive Timeline, entities, data tables, Q&A Connect U
From reprogramming mice to managing trials – are we witnessing a shift at Altos Labs? LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s
Is Altos Labs gearing up for clinical trials? Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Next Health opens flagship ... BCI invests in T
Quartz - Coinbase CEO's anti-aging startup NewLimit is... Facebook Log In Quartz's Post Quartz Verified account June 3 at 8:31 AM · Shared with Public Coinbase CEO's anti-aging startup NewLimit is raising $435 million, tripling its valuation: The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year qz.com NewLimit raises $435M Series C, valuation hits $3.1B Like Comment
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
Altos Labs - In Vivo Engineering Skip to content Register Before Friday, June 26 & Save up to $360 Day Hour Minute Second July 28-30, 2026 | Boston, MA About About Event Poster Session Content Hub Why In Vivo Might be the Biggest Paradigm Shift for Cell and Gene Therapies Why Ex Vivo Companies Can’t Afford to Ignore the Future of In Vivo Therapies How Asia’s Regulatory Ecosystem Is Accelerating In Vivo Clinical Development Benchmarking Your In Vivo Pipeline for 2026: Clinical Signals, Asia IIT Acceleration and What Top Biotechs Are Prioritizing Now From Early Bet to Market Leader: The In V
--> Dorian and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery Welcome to HitGen --> --> CN EN About About Us History News Board of Directors Executive Team Investors Sustainability Publications Download Center Careers DNA Encoded Library DEL for DNA Encoded Library Design and Synthesis DNA Encoded Library Screening OpenDEL ™ Oligonucleotides Nucleic Acid Sequence Design Monomer and Solid Support Chemistry Oligonucleotide Chemistry Conjugate For Nucleic Acid Delivery Medicinal Chemistry Biological Evaluation CDMO Protein Degradation Protein Degradatio … a new class of therapeutics that can rejuvenate cells and tissues. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets that are of interest to Dorian. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Dorian. HitGen is a world leader in the development of the DEL techno
Billionaire-backed "rejuvenation" start-up Altos Labs launches operations | pharmaphorum Skip to main content Friday 26 June 2026 BlueSky linkedin youtube header links Get Newsletters Media Kit Pharmaphorum menu first category News Views & Analysis Deep Dive Equity and Sustainability Research & Development Market Access Oncology Artificial Intelligence Patients & Partnerships GLP-1 Previous Editions Webinars Podcasts Videos Spotlight on ASCO BIO-Europe C-Suite Innovators ESMO Frontiers Health JP Morgan Global Policy Insights Events close SECTION News Views & Analysis
Senior Scientist, Discovery Pharmacology @ Altos Labs | Jobright.ai SIGN IN JOIN NOW Senior Scientist, Discovery Pharmacology jobs in United States Overview Company Apply on Employer Site APPLY NOW Altos Labs · 16 hours ago Senior Scientist, Discovery Pharmacology San Francisco Bay Area, CA Full-time Onsite Senior Level $176K/yr - $226K/yr 6+ years exp Altos Labs is focused on restoring cell health and resilience through cell rejuvenation. They are seeking a Senior Scientist in Discovery Pharmacology to support in vitro pharmacology needs and contribute to drug discovery campaigns, utilizing e … Head of In Vivo Pharmacology & Biomarker Discovery Draft Message to Connect Apply Faster with Autofill Plugin FREE Apply With Autofill
What is Growth Strategy and Future Prospects of Altos Labs Company? – businessmodelcanvastemplate.com Skip to content Framework Templates Blogs Search Cart 0 / $0.00 What Are the Growth Strategies and Future Prospects of Altos Labs? March 20, 2026 ALTOS LABS BUNDLE Get the Full Package: 5 Forces $15 $10 BCG Matrix $15 $10 Canvas $15 $10 Marketing Mix $15 $10 PESTLE $15 $10 SWOT Analysis $15 $10 TOTAL: ADD TO CART Can Altos Labs turn a $3 billion bet into a longevity revolution? Altos Labs burst into view in 2022 with an unprecedented $3 billion war chest and a mission to reset cellular a
Meet Altos Labs, Silicon Valley's latest wild bet on living forever | MIT Technology Review You need to enable JavaScript to view this site. Skip to Content MIT Technology Review Featured Topics Newsletters Events Audio MIT Technology Review Featured Topics Newsletters Events Audio Biotechnology and health Meet Altos Labs, Silicon Valley’s latest wild bet on living forever Funders of a deep-pocketed new "rejuvenation" startup are said to include Jeff Bezos and Yuri Milner. By Antonio Regalado archive page September 4, 2021 Alamy, Getty (Bezos) Last October, a large group of scie … at can accurately measure human aging. Shinya Yamanaka, who shared a 2012 Nobel Prize for the discovery of reprogramming, will be an unpaid senior scientist and will chair the company’s scientific advisory board. Yamanaka’s breakthrough discovery was that with the addition of just four proteins, now known as Yamanaka factors, cells can be instructed to revert to a primitive state with the properties of embryonic stem cells. By 2016, Izpisúa Belmonte’s lab had applied these fa … dvisory board including Yamanaka and Jennifer Doudna, who shared a Breakthrough Prize in 2015 and later a Nobel in 2020 for her co-discovery of CRISPR genome editing. Related Story Want to know when you're going to die? Read next Sometime during 2021, however, a new plan emerged to make the research move even faster by turning the idea into a well-funded company that is now Altos. That effort took shape under the direction of Richard Klausner, the one-time chief of the Nation … s not involved in Altos but he did speak at the 2020 meeting and applied for an award from Milky Way. A science business Altos hasn’t made an official announcement yet, but it was incorporated in Delaware this year and a securities disclosure filed in California in June indicates the company has raised at least $270 million, according to Will Gornall, a business school professor at the University of British Columbia who reviewed the document. In addition to Bezos and Milner,
Job Application for Senior Scientist I/II: Investigative Pathologist at Altos Labs Back to jobs Senior Scientist I/II: Investigative Pathologist San Francisco Bay Area, CA Apply Our Mission Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury, and the disabilities that can occur throughout life. For more information, see our website at altoslabs.com. Our Value Our Single Altos Value: Everyone Owns Achieving Our Inspiring Mission . Diversity at Altos Altos Labs has been named one of the Top 3 Biotech Companies and ranked for the second year o … sp; This position is ideal for candidates who have successfully completed their Residency Training Program and graduate studies and are seeking practical, hands-on experience, mentorship, and career development.The role will work closely with the Senior Director of Pathology, alongside cross-functional team members, to deliver high-quality pathology data that informs target selection, translational strategy, safety assessment, and development decisions. You will be part … al-based research. Typically have 7 years + experience (including education and residency training). Be a clear and influential communicator, with the ability to give and receive feedback to improve on outcomes and impact. Have strong demonstrable influencing skills that demonstrate strong thought partnership and judgement, which creates effective relationships with internal and external groups and individuals Strong scientific aptitude and ability to implement in … de-offs Qualifications Doctor of Veterinary Medicine (DVM) and formal pathology residency training (DACVP or DECVP certification or eligibility) PhD in Pathology or closely related discipline highly desirable. Demonstrable understanding of how to work effectively in cross-functional research teams Salary Range: Redwood City Senior Scientist I, Pathology $213,000- $273,200 Senior Scientist II, Pathology $265,000- $339,700 Equal Opportunity Employment We value collaboration and … Altos Labs? Get future opportunities sent straight to your email. Create alert Apply for this job * indicates a required field Quick Apply with MyGreenhouse First Name * Last Name * Preferred First Name Email * Phone Country Phone Resume/CV Attach Attach Dropbox Google Drive Enter manually Enter manually Accepted file types: pdf, doc, docx, txt,
Altos Labs raises $3 billion for aging research | Ron Leuty posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … t, let vaccine-denier voices shape public opinion, and lately, undercut the NIH grant system—especially hurting universities, long the backbone of U.S. biotech innovation. The article speaks mainly to biotech believers—it’s preaching to the choir. But Sarah Reingewirtz of the Los Angeles Daily News: no one in Washington is listening. It’s a strong piece, but echoing in a chamber of those who already agree—not among decision-makers. The real issue isn’t lack of private sector … versity research, and entrepreneurial commercialization used to sync well. Now, grant politics, underfunded universities, and young scientists discouraged by conformity hinder progress. Without a robust public science base, “unleashing” the private sector is like sending a runner onto ruined ground. Over consolidation is also killing innovation. When only a few pharma giants control output, pricing, and IP, creativity suffers. The generic market, once a competitive force, has … al Circuit redefines obviousness in pharma • AT&T & Nokia: $166M patent award overturned • USPTO boosts Patent Center security and litigation tracking 🌐 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗡𝗲𝘄𝘀 • PTAB tightens review standards to curb repeat challenges • EPO allows color drawings in filings • UK IPO advances digital transformation with One IPO Patents 💡 𝗧𝗲𝗰𝗵𝗻𝗼 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 • AI-driven drug delivery, GLP-1 advances, and fracture-healing glues headline Life Sciences. • M
Altos Labs Wins Generalist Prize at Arc Institute's Virtual Cell Challenge | Fay Lin, PhD posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo … Content People Learning Jobs Games Join now Sign in Altos Labs Wins Generalist Prize at Arc Institute's Virtual Cell Challenge Fay Lin, PhD 6mo Edited Report this post Altos Labs has taken home the Generalist Prize at Arc Institute 's Virtual Cell Challenge! The public competition, sponsored by NVIDIA , 10x Genomics , and Ultima Genomics , declared not one, but TWO grand prizes, worth $100,000 each, to the machine learning models that “best” predicted how cells responded to … the challenge of defining robust benchmarks for complex biology. The Generalist Prize emerged mid-competition when one of the three evaluation metrics (mean absolute error) was no longer influencing the leaderboard, allowing top performers to raise their score without accounting for all metrics. The additional prize category uses seven metrics total (3 original challenge metrics plus 4 from Arc’s STATE model) to improve evaluation of biological relevance. Rory Stark emphasize … ology News ): https://lnkd.in/gKZsMGJn NeurIPS 2025: Altos Labs Wins Generalist Prize at Arc's Virtual Cell Challenge genengnews.com 65 2 Comments Like Comment Share Copy LinkedIn Facebook X John Guerrero 6mo Report this comment Fay Lin, PhD , what an impressive achievement. it's inspiring to see how collaboration can reshape our understanding of complex biology. 🌱 #innovation Like Reply 1 Reaction Kresnier Jeffrey Perez 6mo Report this comment Fay Lin, PhD , real succe … followers 6mo Edited Report this post NeurIPS 2025: Altos Labs Wins Generalist Prize at Arc Institute 's Virtual Cell Challenge The public competition, sponsored by NVIDIA , 10x Genomics , and Ultima Genomics , declared not one, but two grand prizes, worth $100,000 each, to the machine learning models that “best” predicted how cells responded to
Altos Labs Inc. H-1B & PERM Sponsorship Data | Visa Bulletin U.S. Immigration Data Priority dates, work visas, and labor market data Visa Bulletin Salaries Roles Employers FAQ About Contact Support Altos Labs Inc. H-1B & Green Card Sponsorship Data Source: US Dept of Labor. Represents Base Salary only. Excludes RSUs, signing bonuses, and variable compensation. View All Salary Records Search for another employer Years of Data Last 3 Years Last 5 Years Last 10 Years All Available Years Visa Program All Programs H-1B Only Green Card Only 2 Total Filings 2021-Present 100.0% Approval Rate C
Altos Labs acquires Dorian Therapeutics – BeBeez International No Result View All Result Private Data Membership options Login COUNTRY ITALY IBERIA FRANCE UK&IRELAND BENELUX DACH SCANDINAVIA&BALTICS PRIVATE EQUITY VENTURE CAPITAL PRIVATE DEBT DISTRESSED ASSETS REAL ESTATE FINTECH GREEN PREMIUM ItaHub HOT ItaHub Legal ItaHub Tax ItaHub Trend REPORT INSIGHT VIEW Private Data Subscribe COUNTRY ITALY IBERIA FRANCE UK&IRELAND BENELUX DACH SCANDINAVIA&BALTICS PRIVATE EQUITY VENTURE CAPITAL PRIVATE DEBT DISTRESSED ASSETS REAL ESTATE FINTECH GREEN PREMIUM ItaHub HOT ItaHub Legal … further resources from Stanford-StartX . Blumberg Capital, The Longevity Fund and Pacific8 later poured resources in the business . In 2022, Altos Labs secured 3 billion from Foresite Capital, ARCH Venture Partners, Altitude Life Science Ventures , Yuri Milner (the founder of Mail.Ru and of DST Global), and Amazon ’s founder Jeff Bezos . Altos Labs also hired nobel laureates Frances Arnold , Jennifer Doudna , Shin
Altos Labs Announces Sponsored Research Agreement with Kyoto University's CiRA to Foster Cellular Rejuvenation Programming Research Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multi … signed a sponsored research agreement with the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University . Effective May 1 of this year, Altos has committed to fund four CiRA research projects for five years to investigate aspects of cellular rejuvenation programming. Continue Reading Altos announces sponsored research agreement with CiRA. "Altos is eager to support the best researchers around the world to unlock the incredible potential of cellular reju … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Altos Labs launches with the goal to transform medicine through cellular rejuvenation programming Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All P … or. Shinya Yamanaka , MD, PhD (Director of the Center for iPS Cell Research and Application at Kyoto University and Nobel Laureate), will serve as senior scientific advisor to Altos without remuneration, overseeing research activities in Japan . "I am deeply honored to have been offered this once in a lifetime opportunity to lead such a unique company with a transformative mission to reverse disease," said Hal Barron . "It's clear from work by Shinya Yamanaka , and many other … and stress. Dr. Walter is the recipient of numerous awards, including the Shaw Prize, the Lasker Award for Basic Medical Research, the Vilcek Prize for Biomedical Science, and the Breakthrough Prize in Life Sciences. He is a member of the National Academy of Sciences, American Academy of Arts and Sciences, the National Academy of Medicine, and the National Academy of Inventors. Prior to joining Altos, Dr. Walter was professor in the Department of Biochemistry/Biophysics at t … rejuvenation. He was the recipient of a National Science Foundation Creativity Award, a National Institutes of Health Director's Pioneer Award, the William Clinton Presidential Award, the Pew Scholar Award, the Gold Medal of Castilla-La Mancha, and the Roger Guillemin Endowed Nobel Chair. Prior to Altos, Dr. Izpisua Belmonte was professor in the Gene Expression Laboratory and the Roger Guillemin chair at the Salk Institute in La Jolla , California. The Altos Cambridge … or of the Babraham Institute in Cambridge . He is the recipient of the Wellcome Prize in Physiology and is a member of the European Molecular Biology Organisation and the Academia Europaea, a Fellow of the Academy of Medical Sciences and of the Royal Society. Altos will also support activities in Japan , guided by Shinya Yamanaka , MD, PhD, who w
Biotech Altos Labs emerges with $3B in funding to focus on 'cellular rejuvenation programming' - Drug Discovery and Development Drug Discovery and Development Home Drug Discovery and Development Drug Discovery Women in Pharma and Biotech Oncology Neurological Disease Infectious Disease Resources Video features Podcast Views Webinars Pharma 50 2026 Pharma 50 2025 Pharma 50 2024 Pharma 50 2023 Pharma 50 2022 Pharma 50 2021 Pharma 50 Advertise SUBSCRIBE Biotech Altos Labs emerges with $3B in funding to focus on ‘cellular rejuvenation programming’ By Brian Buntz | January 20, … has also recruited noted Spanish biochemist Juan Carlos Izpisúa Belmonte, Nobel Prize-winner Shinya Yamanaka and Steve Horvath, who developed the Horvath aging clock. Heading up AI efforts will be Thore Graepel, who is currently research lead at Google DeepMind and a professor of computer science at the University College London. The DeepMind lab made a splash in late 2020 when it accurately predicted protein structures . The company has facilities in the San Francisco Bay Ar
Altos Labs snaps up Dorian Therapeutics Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Next Health opens flagship ... BCI invests in Toleran
Altos Labs, Inc. Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute d … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Altos Labs, Inc. - overview Established 2021 Location Redwood City, CA, US Primary Industry Biotechnology About Based in California, US, and founded in 2021, Altos Labs, Inc. aka Altos, is a biotechnology company focused on cellular rejuvenation programming. Hans Bishop and Richard Klausner are the co-foun … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
Altos Labs Broadens Scope to Senotherapeutics via Acquisition – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » May 30th, 2025 Alt … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room | Resources | About Read our terms and conditions and privacy poli
Dorian Therapeutics - Blumberg Capital Skip to content Our Approach Companies Team News & Insights Search Companies We are proud to be among the first investors and long-term partners to industry leaders who are empowering individuals and businesses through the innovative use of AI and other transformative technologies. Home > Companies > Dorian Therapeutics Dorian Therapeutics Share Dorian Therapeutics is a pre-clinical Silicon Valley biotech focused on developing treatments that counteract aging in degenerative diseases and during cellular therapy. Dorian’s innovative therap … cked by several venture capital firms including Blumberg Capital, The Longevity Fund, and Pacific8, as well as top biotech incubators including Y Combinator and StartX. Our Approach Companies Our Team News & Insights Careers Miami 16690 Collins Avenue., #1204 Sunny Isles Beach, FL 33160 San Francisco 432 Bryant Street San Francisco, CA 94107 New York 575 Lexington Ave New York, NY 10022 Tel Aviv 39 Montefiore Street Tel Aviv, 6520108, Israel Email [email protected]
Company: Altos Labs Logo mobilemenu close CMN Live Home Clinical Trials CMN DB 2.0 CRISPRMED CRISPRMED24 CRISPRMED25 CRISPRMED26 WDC CRISPRMED26 Contest CRISPRMED26 Conference Kit CRISPRMED27 CRISPRMED Website Policies EGMEDC CMN Intelligence Webinars CMN Webinars On-demand - All CMN Webinar - Disrupting the Care of Cardiovascular Disease With Single-Course Gene Editing Medicines CMN Webinar - Taking the Guesswork Out of Drug Development: CRISPR-Select Validates Drug Targets and Drug Responders Early and Conclusively CMN Webinar - Clinical-Grade gRNA for Genomic Medicines: Making Sense of the … rapeutics has received U.S. FDA clearance of its Investigational New Drug (IND) application for BEAM-304, an in vivo base-editing therapy for... CARBON Newsletter (19 June 2026) - Your Latest... Carbon Jun. 19, 2026 Some of the best links we picked up around the internet Scaling CRISPR-based gene editing through advanced... Sponsored content Jun. 18, 2026 Addressing manufacturing bottlenecks in the transition to clinical scale. Clinical: Single CRISPR Infusion Curbs Hereditar
Altos Labs buys Dorian Therapeutics for aging research | Kyle LaHucik posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
Altos Labs About About Science Careers Careers Featured Contact Your browser does not support the video tag. Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life featured News and Perspectives Press Releases Altos Labs appoints Joan Mannick, M.D., as Chief Medical Officer and Head of Product Development Read More Updates Altos Labs lau
Altos Labs About About Science Careers Careers Featured Contact featured Stay up to date with Altos Stay up to date with Altos Category: All Layout: Default / List Press Releases Altos Labs appoints Joan Mannick, M.D., as Chief Medical Officer and Head of Product Development In this role, Dr. Mannick will help drive Altos’ mission to reverse disease through cellular rejuvenation programming and bring transformative therapies to patients. Read more Updates Altos Labs launches Institute of Computation The Institute, which will drive industry-leading advances in AI and computational biology, focu … ular resilience. Read more Updates Peter Walter receives Frontiers of Knowledge Award in Biology and Biomedicine Peter Walter, a Distinguished Investigator in our Bay Area Institute, received the BBVA Foundation’s Frontiers of Knowledge Award in Biology and Biomedicine. Read more News / Inverse The Inverse reports on 'the cellular reset' and Altos' approach to reversing disease Just like the tried-and-true fix for all electronic appliances that go haywire only … nesis of Altos with Endpoints News The big idea here is that a network of Nobel Prize winners and other scientific luminaries allied with some top industry insiders and committed deep-pocket investors can go deep into the biology of cellular rejuvenation — a dream for Klausner, who has one of the best networks of cell researchers and investors in the business — to find durable therapies for a myriad of diseases while reversing the damage of disease, injury and disabilities. R
Altos Labs - About About About Science Careers Careers Featured Contact about Imagine a world where disease reversal is possible Imagine a world where disease reversal is possible A New Model Scientific freedom focused on making medicines Altos merges the best of academia and industry to discover and develop medicines that can transform people’s lives. From academia, the freedom to pursue the most challenging problems in biology, and from industry, the drive, mission and focus on patients. This model promotes deep collaborations, and harnesses the passion and commitment required to transform s
--> Altos Labs appoints Joan Mannick as CMO to advance cellular rejuvenation Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics
I am delighted to announce that I have joined Altos labs as Chief Medical Officer. It is a dream job for me to be able to work with the great scientists at Altos to find new ways to reverse disease… | Joan Mannick | 115 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update yo
Altos Labs hires Joan Mannick as new CMO, a geroscience expert | Kyle LaHucik posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, y
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Altos Labs appoints Joan Mannick, M.D., as Chief Medical Officer and Head of Product Development About About Science Careers Careers Featured Contact Press Releases Altos Labs appoints Joan Mannick, M.D., as Chief Medical Officer and Head of Product Development Copy URL / LinkedIn / Twitter Altos Labs (Altos) today announced that Joan Mannick, M.D., has joined the company as Senior Vice President, Chief Medical Officer, and Head of Product Development. In this role, Dr. Mannick will help drive Altos’ mission to reverse disease through cellular rejuvenation programming and bring transformative … tation Read More Read More Updates Peter Walter receives Frontiers of Knowledge Award in Biology and Biomedicine Read More Read More Home About Science Careers Featured Contact © 2026 Altos Labs • ALTOS and ALTOS LABS are trademarks of Altos Labs, Inc. Privacy Policy | Legal Notices | FAQ | Cookie Preferences | |
Altos Labs About About Science Careers Careers Featured Contact About / Executive Leadership Joan Mannick, MD SVP, Chief Medical Officer and Head of Product Development SVP, Chief Medical Officer and Head of Product Development " Altos has gathered together some of the world’s greatest scientists to discover ways to reverse disease. That is an incredibly ambitious and exciting mission that will change the practice of medicine. I am thrilled to be able to help bring this groundbreaking science to patients. " Dr. Joan Mannick is the Senior Vice President, Chief Medical Officer and Hea
Joanne Mannick Joining Altos Labs - Rapamycin Longevity News Rapamycin Longevity News Joanne Mannick Joining Altos Labs CronosTempi August 6, 2025, 12:04am #1 Joanne Mannick is joining Altos Labs as Chief Medical Officer. What does this mean for Tornado Therapeutics? Is she leaving the company she co-founded? linkedin.com I am delighted to announce that I have joined Altos labs as Chief Medical... I am delighted to announce that I have joined Altos labs as Chief Medical Officer. It is a dream job for me to be able to work with the great scientists at Altos to find new ways to reverse disease t
Altos Labs About About Science Careers Careers Featured Contact Your browser does not support the video tag. Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life featured News and Perspectives Press Releases Altos Labs appoints Joan Mannick, M.D., as Chief Medical Officer and Head of Product Development Read More Updates Altos Labs lau
Jobs at Altos Labs | Biocom You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Jobs Companies Resources Guide for Job Seekers Guide for Biocom California Member Companies Member Sign In Home Jobs Companies Resources Guide for Job Seekers Guide for Biocom California Member Companies Member Sign In Powered by Consider Privacy Terms 10996 Torreyana Road, Suite 200 San Diego, CA 92121 (858) 455-0300 Twitter Facebook LinkedIn About Us Contact Us Terms & Policies Support © 2026 Biocom California Institute. All rights reserved.
Altos Labs - Careers About About Science Careers Careers Featured Contact Careers Be part of our mission Be part of our mission About us / Mission Imagine a world where disease reversal is possible We aim to create a future in which as many people as possible live full lives free of disease. Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life. We aim to create a future in which as many people as possible live full lives free of disease. Our mission is to restore cell health and resilience … he people in a way that no other company can match." Stacey Best "The application process was rigorous but worth the effort. Upon meeting the scientists at Altos, the standard for detail was clear. I continually feel humbled to be chosen for this elite team." Christa Caneda "Altos offers a very inclusive working environment that is open-minded, extremely motivating, fascinating, highly dynamic, interactive and intense. Every day, I am learning so many new … he people in a way that no other company can match." Stacey Best "The application process was rigorous but worth the effort. Upon meeting the scientists at Altos, the standard for detail was clear. I continually feel humbled to be chosen for this elite team." Christa Caneda "Altos offers a very inclusive working environment that is open-minded, extremely motivating, fascinating, highly dynamic, interactive and intense. Every day, I am learning so many new … he people in a way that no other company can match." Stacey Best "The application process was rigorous but worth the effort. Upon meeting the scientists at Altos, the standard for detail was clear. I continually feel humbled to be chosen for this elite team." Christa Caneda "Altos offers a very inclusive working environment that is open-minded, extremely motivating, fascinating, highly dynamic, interactive and intense. Every day, I am learning so many new
Jobs at Altos Labs | Foresite Capital You are using an outdated browser. Please upgrade your browser to improve your experience and security. Strategy Portfolio People Careers News Blog Contact Us Home Strategy Portfolio People Careers News Blog Contact Us Foresite Labs Investor Login Terms Privacy Policy Powered by Consider Privacy Terms © 2026 Foresite Capital Management, LLC. Strategy Portfolio People Careers News Blog Contact Us Foresite Labs Investor Login Terms Privacy Policy
Jobs at Altos Labs Current openings at Altos Labs Create a Job Alert Level-up your career by having opportunities at Altos Labs sent directly to your inbox. Create alert Search Department Select... 26 jobs Altos Headquarters Job Senior Counsel II / Corporate Counsel, Transactions New San Francisco Bay Area, CA Senior Executive Assistant San Francisco Bay Area, CA Belmonte Lab Job Scientist, Biological Sciences San Diego, CA Discovery Science Job Scientist I, Molecular and Cell Biology Cambridge, UK Scientist, In Vivo Genomics San Francisco Bay Area, CA Scientist / Senior Scientist, Computation
Altos Labs About About Science Careers Careers Featured Contact Your browser does not support the video tag. Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life Our mission is to restore cell health and resilience through cell rejuvenation to reverse disease, injury and the disabilities that can occur throughout life featured News and Perspectives Press Releases Altos Labs appoints Joan Mannick, M.D., as Chief Medical Officer and Head of Product Development Read More Updates Altos Labs lau